AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, kindly note that the Company has issued the Letter of Confirmation in lieu of Duplicate Share Certificate AARTI DRUGS LTD. - 524348 - Reg. 34 (1) Annual Report.
Pursuant to Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Annual Report of the Company along with Notice of AGM and other Statutory Reports for FY 2021-22 AARTI DRUGS LTD. - 524348 - Notice Of 37Th Annual General Meeting
This is to inform you that 37th Annual General Meeting (''AGM'') of the Company is scheduled to be held on Thursday, August 4, 2022 at 11:30 AM IST through Video Conferencing (''VC'') /Other Audio Visual Means (''OAVM''). AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the copies of newspaper advertisement published in Financial Express (English) and Apla Mahanagar (Marathi), in compliance with the Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020 and Circular No. 02/2021 dated January 13, 2021, intimating inter-alia that 37th Annual General Meeting of the Company will be held on Thursday, August 4, 2022 at 11:30 AM IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM). AARTI DRUGS LTD. - 524348 - Closure of Trading Window
This is to inform that the Trading Window of the Company will remain closed from July 1, 2022 until the expiry of 48 hours after the declaration of Financial Results for the quarter ended on June 30, 2022. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, kindly note that the Company has issued the Letter of Confirmation in lieu of Duplicate Share Certificate. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be attending the meeting with Investors/Analysts (Participants) at the Tarapur facility on Tuesday, June 14, 2022. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company had attended the Investor Conference AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached herewith revised Q4FY22 Results presentation of the Company for your records. Changes have been made in slide number 8, 9, 11 and 13.